Novo Nordisk has secured a significant regulatory victory, following the United States Food and Drug Administration’s approval of its new weight loss pill containing semaglutide. The decision delivers the Danish
All posts tagged in weight loss
12Articles
Illicit Weight Loss Drug Supplier Alluvi Persists with Unlicensed Sales After High Profile MHRA Raid
A company linked to the globe’s largest known seizure of illicit weight-loss medications remains active in the UK market despite regulatory intervention. Alluvi, the firm in question, continues to distribute
Two of the world’s largest pharmaceutical conglomerates have become embroiled in an escalating takeover battle for Metsera, an emerging biotech on the verge of breakthroughs in weight-loss drug innovation. Novo
Weight loss injections have rapidly transformed the British approach to tackling obesity, with an extraordinary surge in private usage. Latest data suggests that 2.5 million adults in the UK—one in
Denmark’s pharmaceutical powerhouse Novo Nordisk is set to axe 9000 jobs, marking one of the most substantial workforce reductions in its history, as the company battles a steeply declining share
Over a million people in the United Kingdom who use weight-loss jabs such as Mounjaro Ozempic and Wegovy may be risking their travel and health insurance due to confusion over
Eli Lilly, one of the world’s largest pharmaceutical companies, has temporarily halted orders of its highly sought-after weight-loss injection, Mounjaro, to the UK. This move comes as the market braces
Eli Lilly, the pharmaceutical giant behind the popular weight loss injection Mounjaro, has announced a substantial price hike for the medication due to take effect in the UK from September.
A leading biopharmaceutical business saw its shares tumble by almost 40 per cent after results from a trial of its much-anticipated weight loss pill failed to meet market expectations. Viking
Shares in Novo Nordisk climbed over five per cent on the Copenhagen exchange after the Danish pharmaceuticals firm received crucial approval from the United States Food and Drug Administration for
A new oral medication weight loss, orforglipron, has shown promising results in a landmark trial, marking a significant step for obesity treatment in the UK. Developed by Eli Lilly, orforglipron
AstraZeneca, one of the world's leading pharmaceutical companies, experienced a significant setback on Tuesday as its stock price plummeted, wiping out £15 billion in market value. This dramatic drop was triggered by a combination of disappointing early data on its weight loss drug candidate and reports of a major fraud case involving company executives in China. Let's delve into the details of these developments and their potential implications for AstraZeneca's future.
